vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and PROCORE TECHNOLOGIES, INC. (PCOR). Click either name above to swap in a different company.
PROCORE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($349.1M vs $180.9M, roughly 1.9× AVANOS MEDICAL, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -10.8%, a 10.1% gap on every dollar of revenue. On growth, PROCORE TECHNOLOGIES, INC. posted the faster year-over-year revenue change (15.6% vs 0.7%). PROCORE TECHNOLOGIES, INC. produced more free cash flow last quarter ($109.2M vs $21.3M). Over the past eight quarters, PROCORE TECHNOLOGIES, INC.'s revenue compounded faster (13.8% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Procore Technologies is an American construction management software as a service company founded in 2002, with headquarters in Carpinteria, California. Procore hosts a platform to connect those involved in the construction industry on a global platform. The software allows for the creation of simplified workflows and displays a consolidated view of construction products that includes the tracking of tasks, management of project workflows, and scheduling.
AVNS vs PCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $349.1M |
| Net Profit | $-1.3M | $-37.6M |
| Gross Margin | 47.5% | 80.1% |
| Operating Margin | 1.4% | -12.3% |
| Net Margin | -0.7% | -10.8% |
| Revenue YoY | 0.7% | 15.6% |
| Net Profit YoY | 99.7% | 39.6% |
| EPS (diluted) | $-0.02 | $-0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $349.1M | ||
| Q3 25 | $177.8M | $338.9M | ||
| Q2 25 | $175.0M | $323.9M | ||
| Q1 25 | $167.5M | $310.6M | ||
| Q4 24 | $179.6M | $302.0M | ||
| Q3 24 | $170.4M | $295.9M | ||
| Q2 24 | $171.7M | $284.3M | ||
| Q1 24 | $166.1M | $269.4M |
| Q4 25 | $-1.3M | $-37.6M | ||
| Q3 25 | $-1.4M | $-9.1M | ||
| Q2 25 | $-76.8M | $-21.1M | ||
| Q1 25 | $6.6M | $-33.0M | ||
| Q4 24 | $-397.3M | $-62.3M | ||
| Q3 24 | $4.3M | $-26.4M | ||
| Q2 24 | $1.8M | $-6.3M | ||
| Q1 24 | $-900.0K | $-11.0M |
| Q4 25 | 47.5% | 80.1% | ||
| Q3 25 | 48.4% | 79.7% | ||
| Q2 25 | 52.6% | 79.1% | ||
| Q1 25 | 53.6% | 79.1% | ||
| Q4 24 | 54.6% | 81.2% | ||
| Q3 24 | 54.5% | 81.4% | ||
| Q2 24 | 55.7% | 83.1% | ||
| Q1 24 | 57.1% | 83.0% |
| Q4 25 | 1.4% | -12.3% | ||
| Q3 25 | 0.1% | -4.4% | ||
| Q2 25 | -42.6% | -9.3% | ||
| Q1 25 | 6.1% | -11.7% | ||
| Q4 24 | -233.0% | -21.9% | ||
| Q3 24 | 7.0% | -12.3% | ||
| Q2 24 | 3.7% | -5.2% | ||
| Q1 24 | 2.4% | -7.0% |
| Q4 25 | -0.7% | -10.8% | ||
| Q3 25 | -0.8% | -2.7% | ||
| Q2 25 | -43.9% | -6.5% | ||
| Q1 25 | 3.9% | -10.6% | ||
| Q4 24 | -221.2% | -20.6% | ||
| Q3 24 | 2.5% | -8.9% | ||
| Q2 24 | 1.0% | -2.2% | ||
| Q1 24 | -0.5% | -4.1% |
| Q4 25 | $-0.02 | $-0.25 | ||
| Q3 25 | $-0.03 | $-0.06 | ||
| Q2 25 | $-1.66 | $-0.14 | ||
| Q1 25 | $0.14 | $-0.22 | ||
| Q4 24 | $-8.64 | $-0.42 | ||
| Q3 24 | $0.09 | $-0.18 | ||
| Q2 24 | $0.04 | $-0.04 | ||
| Q1 24 | $-0.02 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $768.5M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $1.3B |
| Total Assets | $1.1B | $2.2B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $768.5M | ||
| Q3 25 | $70.5M | $684.0M | ||
| Q2 25 | $90.3M | $620.9M | ||
| Q1 25 | $97.0M | $566.7M | ||
| Q4 24 | $107.7M | $775.4M | ||
| Q3 24 | $89.0M | $756.9M | ||
| Q2 24 | $92.2M | $735.4M | ||
| Q1 24 | $75.8M | $744.6M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $1.3B | ||
| Q3 25 | $778.0M | $1.2B | ||
| Q2 25 | $776.3M | $1.2B | ||
| Q1 25 | $839.4M | $1.2B | ||
| Q4 24 | $828.5M | $1.3B | ||
| Q3 24 | $1.2B | $1.3B | ||
| Q2 24 | $1.2B | $1.3B | ||
| Q1 24 | $1.2B | $1.2B |
| Q4 25 | $1.1B | $2.2B | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $1.0B | $2.0B | ||
| Q1 25 | $1.1B | $1.9B | ||
| Q4 24 | $1.2B | $2.1B | ||
| Q3 24 | $1.7B | $2.0B | ||
| Q2 24 | $1.7B | $2.0B | ||
| Q1 24 | $1.7B | $1.9B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $114.9M |
| Free Cash FlowOCF − Capex | $21.3M | $109.2M |
| FCF MarginFCF / Revenue | 11.8% | 31.3% |
| Capex IntensityCapex / Revenue | 3.8% | 1.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $282.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $114.9M | ||
| Q3 25 | $14.0M | $88.5M | ||
| Q2 25 | $6.8M | $30.8M | ||
| Q1 25 | $25.7M | $66.0M | ||
| Q4 24 | $57.9M | $29.1M | ||
| Q3 24 | $23.0M | $39.3M | ||
| Q2 24 | $27.8M | $58.7M | ||
| Q1 24 | $-8.0M | $69.1M |
| Q4 25 | $21.3M | $109.2M | ||
| Q3 25 | $7.0M | $83.1M | ||
| Q2 25 | $-4.2M | $27.9M | ||
| Q1 25 | $19.0M | $62.0M | ||
| Q4 24 | $53.1M | $17.4M | ||
| Q3 24 | $20.0M | $35.7M | ||
| Q2 24 | $21.9M | $56.8M | ||
| Q1 24 | $-12.1M | $67.1M |
| Q4 25 | 11.8% | 31.3% | ||
| Q3 25 | 3.9% | 24.5% | ||
| Q2 25 | -2.4% | 8.6% | ||
| Q1 25 | 11.3% | 20.0% | ||
| Q4 24 | 29.6% | 5.8% | ||
| Q3 24 | 11.7% | 12.1% | ||
| Q2 24 | 12.8% | 20.0% | ||
| Q1 24 | -7.3% | 24.9% |
| Q4 25 | 3.8% | 1.6% | ||
| Q3 25 | 3.9% | 1.6% | ||
| Q2 25 | 6.3% | 0.9% | ||
| Q1 25 | 4.0% | 1.3% | ||
| Q4 24 | 2.7% | 3.9% | ||
| Q3 24 | 1.8% | 1.2% | ||
| Q2 24 | 3.4% | 0.7% | ||
| Q1 24 | 2.5% | 0.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
